Viridian Therapeutics Announces Proposed Underwritten Public Offering

Viridian Therapeutics Announces Proposed Underwritten Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Oct 21, 2025-

Viridian Therapeutics, Inc. (VRDN) Stock Analysis: Unpacking A Potential 58% Upside Amidst Clinical Achievements

For investors with an eye on the biotechnology sector, Viridian Therapeutics, Inc. (NASDAQ: VRDN) presents a compelling opportunity with a potential upside of 58.26%, according to current analyst ratings. Headquartered in Waltham, Massachusetts, Viridian is a pioneering player in the healthcare sector, focusing on the discovery, development, and commercialization of therapies for serious and rare diseases. This article explores the key financial…